How many drug targets are there?
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
For the past decade, the number of molecular targets for approved drugs has been debated. Here, we reconcile apparently contradictory previous reports into a comprehensive survey, and propose a consensus number of current drug targets for all classes of approved therapeutic drugs. One striking feature is the relatively constant historical rate of target innovation (the rate at which drugs against new targets are launched); however, the rate of developing drugs against new families is significantly lower. The recent approval of drugs that target protein kinases highlights two additional trends: an emerging realization of the importance of polypharmacology, and also the power of a gene-family-led approach in generating novel and important therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, G-protein-coupled receptors (GPCRs) are influenced by trafficking progress and then internalized in the cell membrane and recycled or degraded.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [127]
In the citing paper
“Covalent molecules may not be able to effectively target GPCRs during this turnover process [127].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [127]
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The Pfam Protein Families Database
Bateman, A. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.276 · Cited by 14,000
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Murzin, A. G., Brenner, S. E., Hubbard, T., & Chothia, C. (1995) · Journal of Molecular Biology · doi:10.1016/s0022-2836(05)80134-2 · Cited by 7,012 · cited 1×
“Patterns in drug targets In order to identify the familial relationships between all drug targets, we analysed the presence of domains, using the SCO”
MethodDrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“drugs acted primarily through only 120 underlying molecular target”
BackgroundSelf-citationThe Pfam protein families database
Bateman, A. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh121 · Cited by 3,127
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967 · cited 1×
“Imatinib, originally developed as a highly selective inhibitor of c-AB”
BackgroundA small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892 · cited 1×
“(and which target association led to its first approval for chronic myeloid leukaemia), has subsequently been discovered to be have significant activity against several other clinically relevant kinases, such as c-KI”
Background
Research works printed but not linked: 1
- Christensen, C. M. The Innovator's Dilemma: When New Technologies Cause Great Firms to Fail (Harvard Business School Press, Cambridge, 1997).
Cited by
Items 101–200 of 1,024
Doumazane, E., Scholler, P., Zwier, J. M., Trinquet, E., Rondard, P., & Pin, J. (2011) · The FASEB Journal · doi:10.1096/fj.10-163147 · Cited by 324
“Many cell surface receptors organize into multiprotein complexes (1–5), and among them, G-proteincoupled receptors (GPCRs) represent major targets for drug development (6, 7).”
BackgroundProperties and identification of human protein drug targets
Bakheet, T. M., & Doig, A. J. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp002 · Cited by 324
Cryo-EM structure of SARS-CoV-2 ORF3a in lipid nanodiscs
Kern, D. M., Sorum, B., Mali, S. S., Hoel, C. M., Sridharan, S., Remis, J. P., Toso, D. B., Kotecha, A., Bautista, D. M., & Brohawn, S. G. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-021-00619-0 · Cited by 318
Regulation of the immune response and inflammation by histamine and histamine receptors
O’Mahony, L., Akdis, M., & Akdis, C. A. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.06.051 · Cited by 313
Predicting druggable binding sites at the protein–protein interface
Fuller, J. C., Burgoyne, N. J., & Jackson, R. M. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.10.009 · Cited by 310
Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways
López-Giménez, J. F., & González-Maeso, J. (2017) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2017_478 · Cited by 299
“As evidence of their biological relevance, approximately 900 different types of GPCRs have been identified in the human genome; these receptors participate in the majority of the physiological processes including sense perceptions, as well as neuropsychological, cardiovascular, and endocrine functions, and are the the…”
BackgroundThermal proteome profiling monitors ligand interactions with cellular membrane proteins
Reinhard, F. B. M., Eberhard, D., Werner, T., Franken, H., Childs, D., Doce, C., Savitski, M. F., Huber, W., Bantscheff, M., Savitski, M. M., et al. (2015) · Nature Methods · doi:10.1038/nmeth.3652 · Cited by 315
Genomic-scale prioritization of drug targets: the TDR Targets database
Agüero, F., Al-Lazikani, B., Aslett, M., Berriman, M., Buckner, F. S., Campbell, R. K., Carmona, S., Carruthers, I. M., Chan, A. W. E., Chen, F., et al. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2684 · Cited by 306
“Druggability was also inferred using a sequence-feature-based Bayesian algorithm trained on a set of known drug targets 12 .”
BackgroundMethodSelf-citationLigand discovery from a dopamine D3 receptor homology model and crystal structure
Carlsson, J., Coleman, R. G., Setola, V., Irwin, J. J., Fan, H., Schlessinger, A., Sali, A., Roth, B. L., & Shoichet, B. K. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.662 · Cited by 308
“The models were based on two types of templates: (1) the crystal structures of the β1(3) and β2(2) adrenergic receptors and (2) 710 elastic network models produced by 3K-ENM33, based on each of these two crystal structures.”
MethodDiverse activation pathways in class A GPCRs converge near the G-protein-coupling region
Venkatakrishnan, A. J., Deupi, X., Lebon, G., Heydenreich, F. M., Flock, T., Miljus, T., Balaji, S., Bouvier, M., Veprintsev, D. B., Tate, C. G., et al. (2016) · Nature · doi:10.1038/nature19107 · Cited by 308
Advances in self-assembled chitosan nanomaterials for drug delivery
Yang, Y., Wang, S., Wang, Y., Wang, X., Wang, Q., & Chen, M. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.07.007 · Cited by 301
Chemokine receptor antagonists: overcoming developmental hurdles
Horuk, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2734 · Cited by 303
Probing the Probes: Fitness Factors For Small Molecule Tools
Workman, P., & Collins, I. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.05.013 · Cited by 299
Ubiquitin and membrane protein turnover: from cradle to grave
MacGurn, J. A., Hsu, P.-C., & Emr, S. D. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060210-093619 · Cited by 287
In silico design of novel probes for the atypical opioid receptor MRGPRX2
Lansu, K., Karpiak, J., Liu, J., Huang, X.-P., McCorvy, J. D., Kroeze, W. K., Che, T., Nagase, H., Carroll, F. I., Jin, J., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2334 · Cited by 293
“log [drug] (M) 1 2 3 4 Dynorphin A(2-8) Dynorphin A(6-17) Dynorphin A(13-17) Dynorphin B(1-13) α-neoendorphin β-neoendorphin”
A saposin-lipoprotein nanoparticle system for membrane proteins
Frauenfeld, J., Löving, R., Armache, J.-P., Sonnen, A. F.-P., Guettou, F., Moberg, P., Zhu, L., Jegerschöld, C., Flayhan, A., Briggs, J. A. G., et al. (2016) · Nature Methods · doi:10.1038/nmeth.3801 · Cited by 293
The application of principal component analysis to drug discovery and biomedical data
Giuliani, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.005 · Cited by 287
Modulators of 14-3-3 Protein–Protein Interactions
Stevers, L. M., Sijbesma, E., Botta, M., MacKintosh, C., Obsil, T., Landrieu, I., Cau, Y., Wilson, A. J., Karawajczyk, A., Eickhoff, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00574 · Cited by 279
Structure-based discovery of β 2 -adrenergic receptor ligands
Kolb, P., Rosenbaum, D. M., Irwin, J. J., Fung, J. J., Kobilka, B. K., & Shoichet, B. K. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812657106 · Cited by 288
“Over the past 55 years (7), this has resulted in 155 drugs, 32 of which target the "2-adrenergic receptor (8).”
BackgroundBiased agonism: An emerging paradigm in GPCR drug discovery
Rankovic, Z., Brust, T. F., & Bohn, L. M. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.12.024 · Cited by 282
Enkavi, G., Javanainen, M., Kulig, W., Róg, T., & Vattulainen, I. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00538 · Cited by 289
Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics
Lorenzer, C., Dirin, M., Winkler, A.-M., Baumann, V., & Winkler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.003 · Cited by 284
van der Linden, S. C., Heringa, M. B., Man, H.-Y., Sonneveld, E., Puijker, L. M., Brouwer, A., & van der Burg, B. (2008) · Environmental Science & Technology · doi:10.1021/es702897y · Cited by 285
Rask-Andersen, M., Masuram, S., & Schiöth, H. B. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135943 · Cited by 282
Muller, M. P., Jiang, T., Sun, C., Lihan, M., Pant, S., Mahinthichaichan, P., Trifan, A., & Tajkhorshid, E. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00608 · Cited by 282
PDBTM: Protein Data Bank of transmembrane proteins after 8 years
Kozma, D., Simon, I., & Tusnády, G. E. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1169 · Cited by 285
“The fact that half of present-day drugs have some effect on transmembrane proteins (1,2) also underlines their biological importance.”
BackgroundMethodDiversity-oriented synthesis; a spectrum of approaches and results
Spandl, R. J., Bender, A., & Spring, D. R. (2008) · Organic & Biomolecular Chemistry · doi:10.1039/b719372f · Cited by 281
Electrophilic natural products and their biological targets
Gersch, M., Kreuzer, J., & Sieber, S. A. (2012) · Natural Product Reports · doi:10.1039/c2np20012k · Cited by 282
Cimermancic, P., Weinkam, P., Rettenmaier, T. J., Bichmann, L., Keedy, D. A., Woldeyes, R. A., Schneidman-Duhovny, D., Demerdash, O. N., Mitchell, J. C., Wells, J. A., et al. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.01.029 · Cited by 268
“It has been suggested that the human proteome of approximately 20,000 proteins contains ~3000 proteins associated with disease and ~3000 druggable proteins, with the overlap between the two sets of only ~600–1500 [16,53,54].”
BackgroundThe Future of High-Throughput Screening
Mayr, L. M., & Fuerst, P. (2008) · SLAS Discovery · doi:10.1177/1087057108319644 · Cited by 276
“Most of today’s lead-finding efforts are on the left side with the established drug classes.(1,11) Future drug discovery efforts might focus more on the novel target classes summarized on the right side, assuming that the given problems of proper readout technologies and suitable chemical space (drugability) can be ov…”
BackgroundAdvances in therapeutic peptides targeting G protein-coupled receptors
Davenport, A. P., Scully, C. C. G., de Graaf, C., Brown, A. J. H., & Maguire, J. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0062-z · Cited by 275
Cancer as a channelopathy: ion channels and pumps in tumor development and progression
Litan, A., & Langhans, S. A. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00086 · Cited by 276
“About 13% of currently known drugs whose primary therapeutic targets are ion channels are being used for the treatment of a variety of human conditions, including cardiovascular and neurological disorders (Overington et al., 2006).”
BackgroundUpdate of TTD: Therapeutic Target Database
Zhu, F., Han, B., Kumar, P., Liu, X., Ma, X., Wei, X., Huang, L., Guo, Y., Han, L., Zheng, C., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp1014 · Cited by 274
“While drugs typically modulate the activities of multiple proteins (25) and up to 14 000 drug-targeted-proteins have been reported (26), the reported number of primary targets directly related to the therapeutic actions of approved drugs is limited to 324 (6).”
BackgroundYang, H., Qin, C., Li, Y. H., Tao, L., Zhou, J., Yu, C. Y., Xu, F., Chen, Z., Zhu, F., & Chen, Y. Z. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1230 · Cited by 270
“For those drugs without target information or with more than one target (including different targets of the same drug reported in different sources), we conducted additional literature search for finding or verifying their efficacy targets linked to the clinically tested therapeutics using the established criterion of…”
BackgroundMethodOluwole, A. O., Danielczak, B., Meister, A., Babalola, J. O., Vargas, C., & Keller, S. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201610778 · Cited by 273
Pollastri, M. P. (2010) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph0912s49 · Cited by 239
“Since fewer than half of all FDA-approved drugs are Ro5compliant (Overington et al., 2006), it has been suggested that the Ro5 induces an overly stringent bias upon medicinal chemists, adversely impacting innovation.”
BackgroundPsychedelics as anti-inflammatory agents
Flanagan, T. W., & Nichols, C. D. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1481827 · Cited by 267
McPartland, J. M., Glass, M., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707399 · Cited by 266
“Interestingly, the Ki of THC at HsCB1 places it around the median affinity for current small-molecule drugs, which is 20 nM (Overington et al., 2006).”
BackgroundGrinter, S., & Zou, X. (2014) · Molecules · doi:10.3390/molecules190710150 · Cited by 260
“It has been well-recognized that drugs may bind to many targets with significant affinities, and that this drug promiscuity gives rise to a complex polypharmacology with clinical relevance to the toxicity and side effects of pharmaceuticals [3,121].”
BackgroundDrug Design of Zinc‐Enzyme Inhibitors
Supuran, C., & Winum, J.-Y. (2009) · Wiley eBooks · doi:10.1002/9780470508169 · Cited by 263
“Nevertheless, for all classes of approved therapeutic drugs, around 300 targets have been disclosed with increasing frequency: 270 being encoded by the human genome and the remaining belonging to pathogenic organisms.(3,4) Several promising targets for drug intervention have been revealed in recent years, and their kn…”
BackgroundHuman Olfactory Receptors: Novel Cellular Functions Outside of the Nose
Maßberg, D., & Hatt, H. (2018) · Physiological Reviews · doi:10.1152/physrev.00013.2017 · Cited by 262
Conn, P. J., Lindsley, C. W., Meiler, J., & Niswender, C. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4308 · Cited by 260
Extracellular vesicles as a platform for membrane‐associated therapeutic protein delivery
Yang, Y., Hong, Y., Cho, E., Kim, G. B., & Kim, I. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1440131 · Cited by 258
“cell-to-cell interaction, membrane trafficking, and cellular metabolism, membrane proteins are targeted by more than 60% of drugs in clinical use today [23,24].”
BackgroundNanobodies to Study G Protein–Coupled Receptor Structure and Function
Manglik, A., Kobilka, B. K., & Steyaert, J. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104710 · Cited by 257
“The remaining approximately 350 nonsensory GPCRs mediate cell-to-cell signaling and are the targets for a large fraction of clinically used drugs (8, 9), although only a minority of these receptors are exploited therapeutically.”
Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting
Zhu, F., Qin, C., Tao, L., Liu, X., Shi, Z., Ma, X., Jia, J., Tan, Y., Cui, C., Lin, J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107336108 · Cited by 255
“The potential for drug development of a natural product depends not only on its bioactivity but also on the drug-likeness of its structure [optimized for enhanced drug-like (6) and reduced unwanted (20–22) properties] and the susceptibility of its target (“druggability”) to drugs [324 targets are confirmed druggable i…”
BackgroundSchröder, R., Janssen, N., Schmidt, J., Kebig, A., Merten, N., Hennen, S., Müller, A., Blättermann, S., Mohr-Andrä, M., Zahn, S., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1671 · Cited by 256
“Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes.”
BackgroundSequencing studies in human genetics: design and interpretation
Goldstein, D. B., Allen, A., Keebler, J., Margulies, E. H., Petrou, S., Petrovski, S., & Sunyaev, S. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3455 · Cited by 255
Jähnichen, S., Blanchetot, C., Maussang, D., Gonzalez-Pajuelo, M., Chow, K. Y., Bosch, L., De Vrieze, S., Serruys, B., Ulrichts, H., Vandevelde, W., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012865107 · Cited by 250
“GPCRs are targeted therapeuticallymostly by small molecules (1), whereas they appear to be difficult targets for the growing field of antibody-based therapeutic agents.”
BackgroundChemoenzymatic Semisynthesis of Proteins
Thompson, R. E., & Muir, T. W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00450 · Cited by 252
Meanwell, N. A. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00043 · Cited by 239
Improving the odds of drug development success through human genomics: modelling study
Hingorani, A. D., Kuan, V., Finan, C., Kruger, F. A., Gaulton, A., Chopade, S., Sofat, R., MacAllister, R. J., Overington, J. P., Hemingway, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54849-w · Cited by 247
Self-citationWhat makes a good drug target?
Gashaw, I., Ellinghaus, P., Sommer, A., & Asadullah, K. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.09.007 · Cited by 240
Contaminants of emerging concern in a large temperate estuary
Meador, J. P., Yeh, A., Young, G., & Gallagher, E. P. (2016) · Environmental Pollution · doi:10.1016/j.envpol.2016.01.088 · Cited by 237
“study were generally greater than the reported values in VidalDorsch et al. (2012), but lower than the values observed in Charleston Harbor, San Francisco Bay, and the Gulf of Mexico estuaries (Hedgespeth et al.”
BackgroundResultInfluentialEinav, S., Gerber, D., Bryson, P. D., Sklan, E. H., Elazar, M., Maerkl, S. J., Glenn, J. S., & Quake, S. R. (2008) · Nature Biotechnology · doi:10.1038/nbt.1490 · Cited by 235
Multiple Independent Binding Sites for Small-Molecule Inhibitors on the Oncoprotein c-Myc
Hammoudeh, D. I., Follis, A. V., Prochownik, E. V., & Metallo, S. J. (2009) · Journal of the American Chemical Society · doi:10.1021/ja900616b · Cited by 229
Olayan, R. S., Ashoor, H., & Bajic, V. B. (2018) · Bioinformatics · doi:10.1093/bioinformatics/btx731 · Cited by 231
“Through binding, drugs can either enhance or inhibit functions carried out by proteins (Overington et al., 2006; Santos et al., 2017) and thus affect the disease conditions.”
BackgroundKimple, A. J., Bosch, D. E., Giguère, P. M., & Siderovski, D. P. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003038 · Cited by 230
“…genome is dedicated to these receptors (Takeda et al., 2002; Fredriksson et al., 2003; Vassilatis et al., 2003), and nearly a third of the pharmaceuticals currently on the market target one or more of these receptors (Jacoby et al., 2006; Overington et al., 2006; Lagerström and Schiöth, 2008).”
BackgroundDeepLoc 2.1: multi-label membrane protein type prediction using protein language models
Ødum, M. T., Teufel, F., Thumuluri, V., Almagro Armenteros, J. J., Johansen, A. R., Winther, O., & Nielsen, H. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae237 · Cited by 285
“For these reasons, membrane proteins often pose as targets in drug discovery, high-lighting their biological importance for proteomics research ( 2 ,3 ).”
Structure-Based Discovery of A 2A Adenosine Receptor Ligands
Carlsson, J., Yoo, L., Gao, Z.-G., Irwin, J. J., Shoichet, B. K., & Jacobson, K. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100240h · Cited by 227
Stroganov, O. V., Novikov, F. N., Stroylov, V. S., Kulkov, V., & Chilov, G. G. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci800166p · Cited by 223
Reker, D., Rodrigues, T., Schneider, P., & Schneider, G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320001111 · Cited by 227
“In fact, high target promiscuity appears common among drug-like molecules (18).”
BackgroundDrugging Undruggable Molecular Cancer Targets
Lazo, J. S., & Sharlow, E. R. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103440 · Cited by 224
Advances in G Protein-Coupled Receptor Allostery: From Function to Structure
Christopoulos, A. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.094342 · Cited by 220
Mechanistic enzymology in drug discovery: a fresh perspective
Holdgate, G. A., Meek, T. D., & Grimley, R. L. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.219 · Cited by 220
Morelli, X., Bourgeas, R., & Roche, P. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.05.024 · Cited by 223
Conducting Nanomaterial Sensor Using Natural Receptors
Kwon, O. S., Song, H. S., Park, T. H., & Jang, J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00159 · Cited by 223
The Significance of G Protein-Coupled Receptor Crystallography for Drug Discovery
Salon, J. A., Lodowski, D. T., & Palczewski, K. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003350 · Cited by 222
Scaffold diversity of natural products: inspiration for combinatorial library design
Grabowski, K., Baringhaus, K.-H., & Schneider, G. (2008) · Natural Product Reports · doi:10.1039/b715668p · Cited by 218
Chitosan Mediated Targeted Drug Delivery System: A Review
Patel, M. P., Patel, R. R., & Patel, J. K. (2010) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3jc7c · Cited by 214
“[27].”
Cell-Permeable Cyclic Peptides from Synthetic Libraries Inspired by Natural Products
Hewitt, W. M., Leung, S. S. F., Pye, C. R., Ponkey, A. R., Bednarek, M., Jacobson, M. P., & Lokey, R. S. (2015) · Journal of the American Chemical Society · doi:10.1021/ja508766b · Cited by 210
CURRENT PROGRESS IN STRUCTURE-BASED RATIONAL DRUG DESIGN MARKS A NEW MINDSET IN DRUG DISCOVERY
Lounnas, V., Ritschel, T., Kelder, J., McGuire, R., Bywater, R. P., & Foloppe, N. (2013) · Computational and Structural Biotechnology Journal · doi:10.5936/csbj.201302011 · Cited by 213
Keller, J., Catala-Lehnen, P., Huebner, A. K., Jeschke, A., Heckt, T., Lueth, A., Krause, M., Koehne, T., Albers, J., Schulze, J., et al. (2014) · Nature Communications · doi:10.1038/ncomms6215 · Cited by 211
Rescue of defective G protein–coupled receptor function in vivo by intermolecular cooperation
Rivero-Müller, A., Chou, Y.-Y., Ji, I., Lajic, S., Hanyaloglu, A. C., Jonas, K., Rahman, N., Ji, T. H., & Huhtaniemi, I. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906695106 · Cited by 210
Drugs and their molecular targets: an updated overview
Landry, Y., & Gies, J. (2008) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2007.00548.x · Cited by 208
Urwyler, S. (2011) · Pharmacological Reviews · doi:10.1124/pr.109.002501 · Cited by 207
High-content single-cell drug screening with phosphospecific flow cytometry
Krutzik, P. O., Crane, J. M., Clutter, M. R., & Nolan, G. P. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.2007.59 · Cited by 207
“By comparing the inhibition profiles of the eight compounds simultaneously, we gained mechanistic insight into the susceptibility, or “druggability,” of multiple pathways and cell subtype”
BackgroundChu, Y., Kaushik, A. C., Wang, X., Wang, W., Zhang, Y., Shan, X., Salahub, D. R., Xiong, Y., & Wei, D.-Q. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbz152 · Cited by 208
Tatonetti, N. P., Fernald, G. H., & Altman, R. B. (2012) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000214 · Cited by 203
The Endocannabinoid System, Cannabinoids, and Pain
Fine, P. G., & Rosenfeld, M. J. (2013) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10129 · Cited by 178
Affimer proteins are versatile and renewable affinity reagents
Tiede, C., Bedford, R., Heseltine, S. J., Smith, G., Wijetunga, I., Ross, R., AlQallaf, D., Roberts, A. P., Balls, A., Curd, A., et al. (2017) · eLife · doi:10.7554/elife.24903 · Cited by 203
“Affimer binders for modulating ion channel function Ion channels are involved in a number of physiological processes, and are important drug targets (Overington et al., 2006).”
Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology
Blagg, J., & Workman, P. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.005 · Cited by 203
“Given the diversity of druggable proteins (Griffith et al., 2013; Hopkins and Groom, 2002; Overington et al., 2006; Cancer Cell 32, July 10, 2017 11 Box 1.”
BackgroundArchaea — timeline of the third domain
Cavicchioli, R. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2482 · Cited by 195
“Until then, the bacteriorhodopsin structure was the basis for models of the GPCRs, having a notable impact on human health, as the GPCRs represent ∼30% of the targets of medicinal drug”
BackgroundNovel Allosteric Modulators of G Protein-coupled Receptors
Gentry, P. R., Sexton, P. M., & Christopoulos, A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.662759 · Cited by 199
“To date, the majority of probe compounds and marketed drugs that target GPCRs are small molecules, but it is noteworthy that there is a growing interest in utilizing biologics and antibodies to target these receptors as well (6).”
BackgroundLiposome delivery systems for the treatment of Alzheimer’s disease
Ross, C., Taylor, M., Fullwood, N., & Allsop, D. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s183117 · Cited by 198
“12–14 Any effective treatment for AD would most likely require the therapeutic agent concerned to be transported across the blood–brain barrier (BBB), 15 which prevents access to the brain of around 98% of potential neuropharmaceuticals.”
Opportunities for therapeutic antibodies directed at G-protein-coupled receptors
Hutchings, C. J., Koglin, M., Olson, W. C., & Marshall, F. H. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.91 · Cited by 198
Gilbert, I. H. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400362b · Cited by 190
Genome of the human hookworm Necator americanus
Tang, Y. T., Gao, X., Rosa, B. A., Abubucker, S., Hallsworth-Pepin, K., Martin, J., Tyagi, R., Heizer, E., Zhang, X., Bhonagiri-Palsikar, V., et al. (2014) · Nature Genetics · doi:10.1038/ng.2875 · Cited by 195
Kofuku, Y., Ueda, T., Okude, J., Shiraishi, Y., Kondo, K., Maeda, M., Tsujishita, H., & Shimada, I. (2012) · Nature Communications · doi:10.1038/ncomms2046 · Cited by 195
Smith, A. J. T., Zhang, X., Leach, A. G., & Houk, K. N. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800498e · Cited by 193
AI Applications through the Whole Life Cycle of Material Discovery
Li, J., Lim, K., Yang, H., Ren, Z., Raghavan, S., Chen, P.-Y., Buonassisi, T., & Wang, X. (2020) · Matter · doi:10.1016/j.matt.2020.06.011 · Cited by 192
CHARMM-GUI Membrane Builder: Past, Current, and Future Developments and Applications
Feng, S., Park, S., Choi, Y. K., & Im, W. (2023) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.2c01246 · Cited by 186
Targeting breast cancer stem cells
McDermott, S. P., & Wicha, M. S. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.06.005 · Cited by 193
On-chip nanohole array based sensing: a review
Escobedo, C. (2013) · Lab on a Chip · doi:10.1039/c3lc50107h · Cited by 190
Cheminformatic comparison of approved drugs from natural product versus synthetic origins
Stratton, C. F., Newman, D. J., & Tan, D. S. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.07.014 · Cited by 191
Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy
Lee, J. A., Uhlik, M. T., Moxham, C. M., Tomandl, D., & Sall, D. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201649s · Cited by 192
Lysophospholipid receptors in drug discovery
Kihara, Y., Mizuno, H., & Chun, J. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.11.020 · Cited by 189
Docking and chemoinformatic screens for new ligands and targets
Kolb, P., Ferreira, R. S., Irwin, J. J., & Shoichet, B. K. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.08.003 · Cited by 193
“This absence was keenly felt, as 25% of drug targets are GPCRs, and 40% of drugs bind to these targets [33].”
BackgroundPeptide Phage Display as a Tool for Drug Discovery: Targeting Membrane Receptors
Molek, P., Strukelj, B., & Bratkovic, T. (2011) · Molecules · doi:10.3390/molecules16010857 · Cited by 187
“phage-displayed peptide libraries against G protein-coupled receptors (GPCRs) (reviewed in [5]), which constitute the largest class of drug targets [70].”
BackgroundType IV collagen is an activating ligand for the adhesion G protein–coupled receptor GPR126
Paavola, K. J., Sidik, H., Zuchero, J. B., Eckart, M., & Talbot, W. S. (2014) · Science Signaling · doi:10.1126/scisignal.2005347 · Cited by 188
Modelling three-dimensional protein structures for applications in drug design
Schmidt, T., Bergner, A., & Schwede, T. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.10.027 · Cited by 187
“G-protein-coupled receptors (GPCRs) represent the most prominent target class against which almost a third of all FDA-approved drugs are targeted [52].”
Background
Metadata
- Authors
- Overington, J. P., Al-Lazikani, B., & Hopkins, A. L.
- Affiliations
- Pfizer (United Kingdom) (GB)
- Corresponding author
- Overington, John P.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-12
- Volume
- 5
- Issue
- 12
- Pages
- 993-996
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1968682237
- Cited by
- 3,505
- References
- 29
- Citations by year
- 2026: 82 · 2025: 126 · 2024: 117 · 2023: 127 · 2022: 173 · 2021: 168 · 2020: 190 · 2019: 190 · 2018: 198 · 2017: 215 · 2016: 276 · 2015: 268 · 2014: 245 · 2013: 280 · 2012: 247
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- therapeutic target, molecular targets, protein kinases, polypharmacology, approved drugs
- MeSH terms
- Humans, Technology, Pharmaceutical, Drug Design, Drugs, Investigational, Genome, Human, Drug Delivery Systems, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.